NCmax (ng/L/mg) NAUC0-t (ng•hr/mL/mg) Ratio for NCmax Ratio for NAUC0-t (also F) Subject ID 0.2 mg IV 1.1 mg SL 2.2 mg SL 0.2 mg IV 1.1 mg SL 2.2 mg SL 1.1 SL/ IV 2.2 SL/ IV 1.1 SL/ IV 2.2 SL/ IV A01 29.7 5.11 2.74 14.8 9.40 4.92 0.172 0.092 0.635 0.332 A02 18.5 5.61 2.01 9.22 7.54 2.91 0.303 0.109 0.818 0.316 A03 1,000 6.03 3.90 288 6.46 6.15 0.006 0.004 0.022 0.021 A04 561 4.19 2.56 150 6.76 4.88 0.007 0.005 0.045 0.033 A05 103 3.05 3.50 34.2 5.37 4.32 0.030 0.034 0.157 0.126 B01 113 5.73 2.96 52.6 11.3 6.63 0.050 0.026 0.215 0.126 B02 107 3.76 2.02 48.6 6.56 4.75 0.035 0.019 0.135 0.098 B03 17.7 2.63 4.28 29.3 4.19 7.17 0.149 0.242 0.143 0.245 B04 47.8 4.11 2.18 45.7 5.67 3.37 0.086 0.046 0.124 0.074 B05 300 6.58 5.54 88.4 8.02 6.62 0.022 0.018 0.091 0.075 Mean             0.086 0.059 0.239 0.145 SD             0.096 0.073 0.266 0.113 Median 105 4.65 2.85 47.2 6.66 4.90 0.043 0.030 0.139 0.112 Min 17.7 2.63 2.01 9.22 4.19 2.91 0.006 0.004 0.022 0.021 Max 1,000 6.58 5.54 288 11.3 7.17 0.303 0.242 0.818 0.332

Table 5: Bioavailability of 1.1 and 2.2 mg administered sublingually compared to 0.2 mg intravenously for individual subjects.